TY  - JOUR
AU  - Peters, Solange
AU  - Gettinger, Scott
AU  - Johnson, Melissa L
AU  - Jänne, Pasi A
AU  - Garassino, Marina C
AU  - Christoph, Daniel
AU  - Toh, Chee Keong
AU  - Rizvi, Naiyer A
AU  - Chaft, Jamie E
AU  - Carcereny Costa, Enric
AU  - Patel, Jyoti D
AU  - Chow, Laura Q M
AU  - Koczywas, Marianna
AU  - Ho, Cheryl
AU  - Früh, Martin
AU  - van den Heuvel, Michel
AU  - Rothenstein, Jeffrey
AU  - Reck, Martin
AU  - Paz Ares, Luis Gonzaga
AU  - Shepherd, Frances A
AU  - Kurata, Takayasu
AU  - Li, Zhengrong
AU  - Qiu, Jiaheng
AU  - Kowanetz, Marcin
AU  - Mocci, Simonetta
AU  - Shankar, Geetha
AU  - Sandler, Alan
AU  - Felip, Enriqueta
PY  - 2017
DO  - 10.1200/JCO.2016.71.9476
SN  - 0732-183X
UR  - http://hdl.handle.net/20.500.12105/8387
AB  - Purpose BIRCH was designed to examine the efficacy of atezolizumab, a humanized anti-programmed death-ligand 1 (PD-L1) monoclonal antibody, in advanced non-small-cell lung cancer (NSCLC) across lines of therapy. Patients were selected on the basis of...
LA  - eng
KW  - Adult
KW  - Aged
TI  - Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1-Selected Advanced Non-Small-Cell Lung Cancer (BIRCH)
TY  - journal article
ER  -